How Biologics for Eczema Differ From Older Treatments

Biologics for eczema are injectable antibodies that interrupt specific immune signals driving the disease, and they have transformed how moderate-to-severe atopic dermatitis is treated. The first and most studied, dupilumab, blocks two inflammatory proteins that sit at the center of the overactive immune response in eczema skin. Since its approval in 2017, additional biologics targeting different molecules have followed, and five-year data now show that most patients who respond well early on keep improving or stay clear for years. The picture has grown more complex, though, with new drugs aimed at itch-specific pathways, real-world evidence on side effects, and emerging questions about who responds best and when treatment can be dialed back.

How Biologics Differ From Older Treatments

Traditional systemic treatments for eczema, like cyclosporine and methotrexate, suppress broad swaths of the immune system. They work, but they come with monitoring requirements and side effects that limit how long most patients can stay on them. Biologics are different in design: each one is an engineered antibody that latches onto a single molecular target, leaving the rest of the immune system largely alone. That specificity is what allows patients to remain on them for years without the organ toxicity concerns that follow older immunosuppressants.

An indirect comparison of dupilumab against cyclosporine illustrates the gap. At around four months, roughly 78% of dupilumab-treated patients hit a 75% improvement in their eczema severity score, compared with about 56% on cyclosporine. By six to seven months, the difference widened further: 80% versus 47%.¹ The comparison is imperfect because the data come from different trial populations rather than a head-to-head study, but the direction is consistent with what dermatologists see in practice.

The Drugs and What They Target

Four biologics are now approved or in late-stage development for eczema, and they do not all hit the same target. Understanding the differences matters because a patient who does not respond well to one may still benefit from another.

Dupilumab blocks a receptor subunit called IL-4Rα, which is shared by two inflammatory proteins, IL-4 and IL-13. By sitting on this shared receptor, dupilumab shuts down signaling from both molecules at once.² IL-4 and IL-13 are two of the main drivers behind the skin barrier breakdown, inflammation, and thickening that define eczema.³

Tralokinumab and lebrikizumab both target IL-13 alone rather than the receptor, but they bind IL-13 at different spots. Lebrikizumab attaches to an epitope that still allows the IL-13 molecule to be cleared through a natural disposal receptor, whereas tralokinumab blocks that clearance pathway.⁴ Whether that mechanical distinction translates into meaningful clinical differences is still being worked out, but it is the sort of nuance that may eventually help match specific patients to specific drugs.

Nemolizumab takes an entirely different approach. Instead of going after the inflammatory cascade that causes redness and skin damage, it blocks the receptor for IL-31, a cytokine that acts directly on nerve fibers to cause itch.⁵ IL-31 is released by the same immune cells that drive eczema inflammation, but it communicates with the nervous system through its own dedicated receptor on sensory neurons, making it a bridge between the immune flare and the unbearable itch that often bothers patients more than the rash itself.⁶

How Well Do They Work, and for How Long

The strongest long-term data exist for dupilumab, which has now been tracked in open-label extension studies out to five years. At the five-year mark, about 89% of patients who continued treatment achieved at least a 75% improvement in their eczema severity score, and roughly 76% hit the 90% improvement threshold. About two-thirds had skin rated as clear or almost clear by their physician.⁷ Those numbers reflect patients who stayed on therapy, so there is some survivorship bias baked in, but the trajectory is encouraging: improvements continued to accrue through years three, four, and five rather than plateauing early.

The benefit also holds regardless of when a patient’s eczema first appeared. A post-hoc analysis of two large trials found that dupilumab outperformed placebo across all age-of-onset subgroups, whether a person’s eczema began in infancy or showed up for the first time in adulthood.⁸

When patients who had responded well were randomized to continue dupilumab at different frequencies or switch to placebo, those who kept receiving it every one or two weeks maintained a 75% improvement score at a rate of about 72%, while less frequent dosing and placebo saw progressive losses.⁹ That finding carries a practical message: stopping or dramatically spacing out injections after a good response often leads to a return of symptoms, so ongoing treatment is typically necessary.

Biologics in Children

Dupilumab is approved for use in children as young as six months with moderate-to-severe eczema, making it one of the few systemic options available for very young patients. In a phase 3 trial of children aged six months to under six years, about 53% of those on dupilumab achieved at least 75% improvement at week 16, compared with 11% on placebo. Roughly 28% reached clear or almost clear skin versus 4% on placebo.¹⁰

Longer-term pediatric follow-up has been reassuring on safety. In a two-year analysis of infants and young children on dupilumab, most side effects were mild or moderate. One serious drug-related event (a pinworm infection) did not require stopping treatment, and only one case of severe hives led to permanent discontinuation. By week 104, more than 92% of patients had reached that 75% improvement benchmark from their original baseline.¹¹

Side Effects Worth Knowing About

Biologics for eczema do not carry the same organ-toxicity baggage as older immunosuppressants, but they have their own side-effect profile. The most discussed is conjunctivitis. Across dupilumab trials, rates of eye inflammation ranged from about 4% to 31% in treated patients, compared with 2% to 11% on placebo.¹² The eye problems are mostly mild or moderate, and the leading theory involves the loss of mucus-producing cells on the eye’s surface when IL-13 signaling is blocked, which destabilizes the tear film and irritates the tissue underneath.¹³ For most patients, lubricating eye drops manage it; a smaller number need a short course of anti-inflammatory eye drops or, rarely, a switch to a different therapy.

A second recognized reaction is new or changed redness on the face and neck that looks different from the patient’s baseline eczema. This affects somewhere between 4% and 43% of dupilumab-treated patients, a wide range that partly reflects how differently studies define the problem.¹⁴ In a systematic review, about half of affected patients had prior eczema involvement in those areas, but roughly 45% reported symptoms that appeared distinct from their existing disease, raising the possibility that rosacea, contact allergy, or another process may be unmasked when the dominant eczema inflammation recedes.¹⁵

How Biologics Compare With JAK Inhibitors

The other major class of newer eczema treatments is JAK inhibitors, which are oral pills rather than injections. Both approaches target the immune pathways that drive eczema, but they differ in speed, safety profile, and how patients stick with them over time.

Network meta-analyses suggest that the higher doses of certain JAK inhibitors may produce somewhat better short-term skin clearance than biologics, while biologics are generally considered to have a better safety profile.¹⁶ Real-world data from a Spanish healthcare network confirmed this general pattern: JAK inhibitors worked faster in the first weeks, but biologics achieved larger absolute improvements between months four and twelve and had longer treatment persistence. The side-effect profiles diverged, too, with infections and acne more common in the JAK inhibitor group and eye symptoms more common with biologics.¹⁷

Persistence on treatment is a useful real-world proxy for whether a drug keeps working and remains tolerable. In one study tracking patients from 2015 to 2024, about 89% of those started on dupilumab were still on it at both one and two years. That dropped sharply for other options: roughly 66% and 17% for one JAK inhibitor at one and two years, and about 59% and 19% for tralokinumab.¹⁸ Those gaps reflect a mix of loss of efficacy, side effects, and patient preference, but the overall message is that patients tend to stay on dupilumab longer than on competing advanced therapies.

Benefits Beyond the Skin

Because the immune signals that drive eczema also fuel other allergic conditions, blocking them with biologics can improve more than the skin. In patients with coexisting allergic asthma, dupilumab led to significant improvements in asthma control scores and lung function within about four months, benefits that held through twelve months of treatment.¹⁹ Patients with allergic rhinitis saw similar gains in nasal symptom control and quality of life.²⁰ Dupilumab is in fact separately approved for moderate-to-severe asthma driven by the same type 2 immune pathway, so for patients with both conditions, a single treatment can address two diseases at once.

Sleep disruption is one of the most underappreciated consequences of eczema. In a placebo-controlled study, dupilumab significantly improved sleep quality scores by week 12, alongside large reductions in itch and disease severity.²¹ Pooled trial data also showed rapid improvements in anxiety and depression symptoms, starting within two weeks and holding through the study period.²² Whether that reflects direct immune effects on mood or simply the relief of constant itching and lost sleep is an open question, but from a patient’s perspective the distinction may not matter much.

What Happens to the Skin Microbiome

Eczema skin is famously overrun by Staphylococcus aureus, a bacterium whose overgrowth worsens flares and damages the skin barrier. One of the more interesting findings from biologic therapy is that it appears to rebalance the microbial community. After dupilumab treatment, the proportion of S. aureus dropped significantly on both affected and unaffected skin, while beneficial species like S. epidermidis and S. hominis increased.²³ Overall bacterial diversity on affected skin went up, a marker of a healthier microbial ecosystem. Dupilumab also shifted the fungal microbiome.²⁴ These changes were not the primary goal of treatment, but they suggest that calming the immune storm allows the skin’s natural microbial community to recover on its own.

Spacing Out Injections Once You Are Doing Well

The standard dupilumab dose for adults is an injection every two weeks. For patients who achieve stable, well-controlled disease, clinicians have increasingly explored extending that interval to every three or four weeks to reduce burden and cost. A large registry study found that tapering was successful in about 83% of patients who attempted it, with most landing on a three- or four-week schedule. Disease scores ticked up slightly but stayed low.²⁵ A separate study using a patient-centered dosing approach found that those who reduced their dose maintained stable low disease activity and low inflammatory biomarker levels over time.²⁶

Tapering works best when patients have been well-controlled for at least about a year. In one cohort, the average duration of standard-interval treatment before tapering began was roughly 53 weeks.²⁷ There is no formal consensus yet on who is the best candidate, but low disease scores and stable skin for many months are the practical thresholds most clinicians use. Importantly, tapering is not the same as stopping: complete discontinuation still tends to bring symptoms back, as the earlier dose-ranging trial showed.

Vaccines, Pregnancy, and Other Practical Concerns

Because biologics are targeted rather than broadly immunosuppressive, they leave routine immune functions intact. A randomized trial found that patients on dupilumab mounted normal antibody responses to both a tetanus vaccine and a meningococcal polysaccharide vaccine, with response rates virtually identical to placebo.²⁸ That means patients can stay on treatment through their regular vaccination schedule without worrying about reduced protection.

Pregnancy is trickier because no one runs randomized drug trials in pregnant women. The available evidence, drawn from case series, registries, and observational cohorts, is cautiously reassuring. A systematic review and meta-analysis concluded that dupilumab during pregnancy did not appear to increase the risk of miscarriage or birth defects compared with the general population, though the authors stressed that the data remain limited.²⁹ A nationwide retrospective cohort study comparing pregnant women exposed to dupilumab against unexposed controls found no significant drug-associated risk for adverse pregnancy, neonatal, or postpartum outcomes after adjusting for confounders.³⁰ A broader review of biologics used for atopic diseases during pregnancy reached a similar conclusion: women who inadvertently became pregnant on these therapies did not seem to face increased risks.³¹ These findings offer some reassurance but are not a green light for planned use during pregnancy, and the conversation between a patient and their physician still has to weigh the severity of untreated disease against the residual uncertainty.

Why Ethnicity and Immune Subtype May Matter

Eczema is not immunologically identical across all patients. Research on different ethnic groups has found that while overactive type 2 immune signaling is a universal feature, the additional immune pathways involved vary. Asian patients tend to show more activity from a pathway involving IL-17, while Black patients often have a strong type 2/type 22 signature without the IL-17 or type 1 contributions seen in other groups.³² Because current biologics are designed around the type 2 pathway, patients whose disease is primarily type 2-driven may respond better than those with more mixed immune profiles.³³

This is still early-stage thinking. No biologic has been shown to clearly fail in one ethnic group while succeeding in another, and the clinical trials include diverse populations. But the variation in immune subtypes is one reason researchers are interested in precision approaches that match specific patients to specific drugs rather than using a one-size-fits-all sequence.

What Is Coming Next

The most advanced biologics in the pipeline target the OX40-OX40L pathway, a pair of molecules that sustain inflammatory T-cell responses over time. Two candidates, rocatinlimab and amlitelimab, are in phase 2 and 3 trials. Rocatinlimab, which blocks OX40 directly, produced meaningful eczema improvement in a placebo-controlled trial, and the notable finding was that responses persisted for 20 weeks after the drug was stopped.³⁴ Amlitelimab, which targets the partner molecule OX40L, showed significant improvement at week 16 across all dose groups tested in a phase 2b study, with benefits maintained through week 24.³⁵

The prospect of a biologic whose effects linger long after you stop injecting it would represent a genuine shift. Current biologics require indefinite maintenance; a drug that could reset the immune response and then be withdrawn, even temporarily, would change the treatment calculus for patients and payers alike. Whether the OX40 pathway drugs deliver on that promise in larger, longer trials remains to be seen, but the early signal is unlike anything the existing drugs have shown.

The Cost Question

Biologics are expensive, and that reality shapes who gets them and when. An early economic evaluation estimated that for dupilumab to meet a common cost-effectiveness threshold, its annual maintenance price would need to be around $29,000 to $40,000 depending on how much society is willing to pay per year of quality life gained.³⁶ The actual list price has historically exceeded those figures, though manufacturer copay programs, insurance negotiations, and biosimilar competition are beginning to shift the landscape. Dose tapering for well-controlled patients, as discussed above, also has direct cost implications: stretching injections from every two weeks to every three or four weeks cuts drug spending by a third to half while maintaining disease control in most patients who are candidates for it.

For patients navigating the insurance process, prior authorization is nearly universal, and most plans require documented failure of at least one or two conventional therapies before approving a biologic. The process can be frustrating, but the clinical rationale for stepwise escalation is real: a meaningful fraction of eczema patients can be managed with topical therapies and lifestyle measures alone, and biologics carry both cost and injection burden that make sense only when simpler options have genuinely fallen short.